Abstract
Human topoisomerase II (topoII) enzymes are critical in DNA topology modulation within the cell. Importantly, topoII are validated anticancer drug targets due to their association with cancer cell proliferation. The clinically available topoII targeted anticancer drugs such as etoposide, often show harmful side effects and drug resistance. Therefore, new studies revolving around the design of topoII inhibitors are crucial for the discovery of novel, potent and safer anti-cancer therapeutics. We present an ongoing drug design campaign to optimize compounds centered on a recently patented chemical class of topoIIα inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
